Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin benefit: from scabies to COVID-19, an example of serendipity

Bernigaud et al., Annals of Dermatology and Venereology, doi:10.1016/j.annder.2020.09.231
Nov 2020  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 99% Improvement Relative Risk Case 55% Ivermectin for COVID-19  Bernigaud et al.  Prophylaxis Is prophylaxis with ivermectin beneficial for COVID-19? Retrospective 3,131 patients in France Lower mortality (p=0.078) and fewer cases (p=0.012) c19ivm.org Bernigaud et al., Annals of Dermatolog.., Nov 2020 Favorsivermectin Favorscontrol 0 0.5 1 1.5 2+
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 23 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19ivm.org
69 residents of a French care home, median age 90, were treated with ivermectin for a scabies outbreak. 3,062 residents in 45 nearby comparable homes were used as controls. 7 of 69 treated patients had probable or certain COVID-19, with no serious cases and no deaths. In comparable care homes in the same district, matched by age and socio-economic level, there was 22.6% COVID-19 and 5% death.
This is the 23rd of 104 COVID-19 controlled studies for ivermectin, which collectively show efficacy with p<0.0000000001 (1 in 1 sextillion).
51 studies are RCTs, which show efficacy with p=0.00000015.
risk of death, 99.4% lower, RR 0.006, p = 0.08, treatment 0 of 69 (0.0%), control 150 of 3,062 (4.9%), NNT 20, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
risk of case, 55.1% lower, RR 0.45, p = 0.01, treatment 7 of 69 (10.1%), control 692 of 3,062 (22.6%), NNT 8.0.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bernigaud et al., 28 Nov 2020, retrospective, France, peer-reviewed, 12 authors, dosage 200μg/kg days 1, 8, 15, 400μg/kg days 1, 8, 15, two different dosages.
This PaperIvermectinAll
C Bernigaud, D Guillemot, A Ahmed-Belkacem, L Grimaldi-Bensouda, A Lespine, F Berry, L Softic, C Chenost, G Do-Pham, B Giraudeau, S Fourati, O Chosidow, Ap-Hp Dermatologie
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
{ 'indexed': {'date-parts': [[2022, 4, 3]], 'date-time': '2022-04-03T12:39:43Z', 'timestamp': 1648989583678}, 'reference-count': 0, 'publisher': 'Elsevier BV', 'issue': '12', 'license': [ { 'start': { 'date-parts': [[2020, 12, 1]], 'date-time': '2020-12-01T00:00:00Z', 'timestamp': 1606780800000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}], 'content-domain': { 'domain': ['clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2020, 12]]}, 'DOI': '10.1016/j.annder.2020.09.231', 'type': 'journal-article', 'created': { 'date-parts': [[2020, 11, 25]], 'date-time': '2020-11-25T23:01:55Z', 'timestamp': 1606345315000}, 'page': 'A194', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 1, 'title': 'Bénéfice de l’ivermectine\xa0: de la gale à la COVID-19, un exemple de sérendipité', 'prefix': '10.1016', 'volume': '147', 'author': [ {'given': 'C.', 'family': 'Bernigaud', 'sequence': 'first', 'affiliation': []}, {'given': 'D.', 'family': 'Guillemot', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Ahmed-Belkacem', 'sequence': 'additional', 'affiliation': []}, {'given': 'L.', 'family': 'Grimaldi-Bensouda', 'sequence': 'additional', 'affiliation': []}, {'given': 'A.', 'family': 'Lespine', 'sequence': 'additional', 'affiliation': []}, {'given': 'F.', 'family': 'Berry', 'sequence': 'additional', 'affiliation': []}, {'given': 'L.', 'family': 'Softic', 'sequence': 'additional', 'affiliation': []}, {'given': 'C.', 'family': 'Chenost', 'sequence': 'additional', 'affiliation': []}, {'given': 'G.', 'family': 'Do-Pham', 'sequence': 'additional', 'affiliation': []}, {'given': 'B.', 'family': 'Giraudeau', 'sequence': 'additional', 'affiliation': []}, {'given': 'S.', 'family': 'Fourati', 'sequence': 'additional', 'affiliation': []}, {'given': 'O.', 'family': 'Chosidow', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'container-title': 'Annales de Dermatologie et de Vénéréologie', 'original-title': [], 'language': 'fr', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S015196382030627X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S015196382030627X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2020, 11, 26]], 'date-time': '2020-11-26T02:07:37Z', 'timestamp': 1606356457000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S015196382030627X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2020, 12]]}, 'references-count': 0, 'journal-issue': {'issue': '12', 'published-print': {'date-parts': [[2020, 12]]}}, 'alternative-id': ['S015196382030627X'], 'URL': 'http://dx.doi.org/10.1016/j.annder.2020.09.231', 'relation': {}, 'ISSN': ['0151-9638'], 'subject': ['Dermatology'], 'container-title-short': 'Annales de Dermatologie et de Vénéréologie', 'published': {'date-parts': [[2020, 12]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Bénéfice de l’ivermectine\xa0: de la gale à la COVID-19, un exemple de ' 'sérendipité', 'name': 'articletitle', 'label': 'Article Title'}, { 'value': 'Annales de Dermatologie et de Vénéréologie', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.annder.2020.09.231', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'simple-article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': 'Copyright © 2020 Published by Elsevier Masson SAS', 'name': 'copyright', 'label': 'Copyright'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit